Epstein Files Full PDF

CLICK HERE
Technopedia Center
PMB University Brochure
Faculty of Engineering and Computer Science
S1 Informatics S1 Information Systems S1 Information Technology S1 Computer Engineering S1 Electrical Engineering S1 Civil Engineering

faculty of Economics and Business
S1 Management S1 Accountancy

Faculty of Letters and Educational Sciences
S1 English literature S1 English language education S1 Mathematics education S1 Sports Education
teknopedia

  • Registerasi
  • Brosur UTI
  • Kip Scholarship Information
  • Performance
Flag Counter
  1. World Encyclopedia
  2. IL22RA1
IL22RA1
From Wikipedia, the free encyclopedia
Protein-coding gene in the species Homo sapiens

IL22RA1
Available structures
PDBOrtholog search: PDBe RCSB
List of PDB id codes

3DGC, 3DLQ

Identifiers
AliasesIL22RA1, CRF2-9, IL22R, IL22R1, interleukin 22 receptor subunit alpha 1
External IDsOMIM: 605457; MGI: 2663588; HomoloGene: 10943; GeneCards: IL22RA1; OMA:IL22RA1 - orthologs
Gene location (Human)
Chromosome 1 (human)
Chr.Chromosome 1 (human)[1]
Chromosome 1 (human)
Genomic location for IL22RA1
Genomic location for IL22RA1
Band1p36.11Start24,119,771 bp[1]
End24,143,140 bp[1]
Gene location (Mouse)
Chromosome 4 (mouse)
Chr.Chromosome 4 (mouse)[2]
Chromosome 4 (mouse)
Genomic location for IL22RA1
Genomic location for IL22RA1
Band4 D3|4 67.99 cMStart135,455,483 bp[2]
End135,479,451 bp[2]
RNA expression pattern
Bgee
HumanMouse (ortholog)
Top expressed in
  • body of pancreas

  • jejunal mucosa

  • skin of leg

  • skin of abdomen

  • skin of arm

  • pancreatic ductal cell

  • mucosa of ileum

  • duodenum

  • mucosa of colon

  • gingival epithelium
Top expressed in
  • jejunum

  • ileum

  • colon

  • duodenum

  • lip

  • zone of skin

  • yolk sac

  • esophagus

  • liver

  • human kidney
More reference expression data
BioGPS
n/a
Gene ontology
Molecular function
  • interferon receptor activity
  • protein binding
  • interleukin-20 binding
  • cytokine receptor activity
Cellular component
  • integral component of membrane
  • membrane
  • plasma membrane
Biological process
  • defense response to Gram-negative bacterium
  • biological process
  • cytokine-mediated signaling pathway
Sources:Amigo / QuickGO
Orthologs
SpeciesHumanMouse
Entrez

58985

230828

Ensembl

ENSG00000142677

ENSMUSG00000037157

UniProt

Q8N6P7

Q80XZ4

RefSeq (mRNA)

NM_021258

NM_178257

RefSeq (protein)

NP_067081

NP_839988

Location (UCSC)Chr 1: 24.12 – 24.14 MbChr 4: 135.46 – 135.48 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Interleukin 22 receptor, alpha 1 is a protein that in humans is encoded by the IL22RA1 gene.[5]

Function

[edit]

The protein encoded by this gene belongs to the class II cytokine receptor family, and has been shown to be a receptor for interleukin 22 (IL22). IL22 receptor is a protein complex that consists of this protein and interleukin 10 receptor, beta (IL10RB/CRFB4), a subunit also shared by the receptor complex for interleukin 10 (IL10). This gene and interleukin 28 receptor, alpha (IL28RA) form a cytokine receptor gene cluster in the chromosomal region 1p36.

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000142677 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000037157 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ "Entrez Gene: Interleukin 22 receptor, alpha 1".

Further reading

[edit]
  • Bleicher L, de Moura PR, Watanabe L, Colau D, Dumoutier L, Renauld JC, Polikarpov I (September 2008). "Crystal structure of the IL-22/IL-22R1 complex and its implications for the IL-22 signaling mechanism". FEBS Letters. 582 (20): 2985–92. doi:10.1016/j.febslet.2008.07.046. PMID 18675809. S2CID 20952148.
  • Jones BC, Logsdon NJ, Walter MR (September 2008). "Structure of IL-22 bound to its high-affinity IL-22R1 chain". Structure. 16 (9): 1333–44. doi:10.1016/j.str.2008.06.005. PMC 2637415. PMID 18599299.
  • de Moura PR, Watanabe L, Bleicher L, Colau D, Dumoutier L, Lemaire MM, Renauld JC, Polikarpov I (April 2009). "Crystal structure of a soluble decoy receptor IL-22BP bound to interleukin-22". FEBS Letters. 583 (7): 1072–7. doi:10.1016/j.febslet.2009.03.006. PMID 19285080.
  • Dumoutier L, de Meester C, Tavernier J, Renauld JC (September 2009). "New activation modus of STAT3: a tyrosine-less region of the interleukin-22 receptor recruits STAT3 by interacting with its coiled-coil domain". The Journal of Biological Chemistry. 284 (39): 26377–84. doi:10.1074/jbc.M109.007955. PMC 2785325. PMID 19632985.
  • Wu PW, Li J, Kodangattil SR, Luxenberg DP, Bennett F, Martino M, Collins M, Dunussi-Joannopoulos K, Gill DS, Wolfman NM, Fouser LA (October 2008). "IL-22R, IL-10R2, and IL-22BP binding sites are topologically juxtaposed on adjacent and overlapping surfaces of IL-22". Journal of Molecular Biology. 382 (5): 1168–83. doi:10.1016/j.jmb.2008.07.046. PMID 18675824.
  • Meng S, Gui Q, Xu Q, Lu K, Jiao X, Fan J, Ge B, Ke Y, Zhang S, Wu J, Wang C (August 2010). "Association of Shp2 with phosphorylated IL-22R1 is required for interleukin-22-induced MAP kinase activation". Journal of Molecular Cell Biology. 2 (4): 223–30. doi:10.1093/jmcb/mjq017. PMC 2948820. PMID 20671117.
  • Kotenko SV, Izotova LS, Mirochnitchenko OV, Esterova E, Dickensheets H, Donnelly RP, Pestka S (January 2001). "Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta ) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes". The Journal of Biological Chemistry. 276 (4): 2725–32. doi:10.1074/jbc.M007837200. PMID 11035029.
  • Chang Y, Al-Alwan L, Risse PA, Halayko AJ, Martin JG, Baglole CJ, Eidelman DH, Hamid Q (December 2012). "Th17-associated cytokines promote human airway smooth muscle cell proliferation". FASEB Journal. 26 (12): 5152–60. doi:10.1096/fj.12-208033. PMID 22898922. S2CID 205369384.
  • Shioya M, Andoh A, Kakinoki S, Nishida A, Fujiyama Y (March 2008). "Interleukin 22 receptor 1 expression in pancreas islets". Pancreas. 36 (2): 197–9. doi:10.1097/MPA.0b013e3181594258. PMID 18376313. S2CID 26713011.

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

  • v
  • t
  • e
Cytokine receptors
Chemokine receptor
(GPCRs)
CC
  • CCR1 / CCRL1
  • CCR2
  • CCRL2
  • CCR3
  • CCR4
  • CCR5
  • CCR6
  • CCR7
  • CCR8
  • CCR9
  • CCR10
CXC
  • IL-8
    • CXCR1
    • CXCR2
  • CXCR3
  • CXCR4
  • CXCR5
  • CXCR6
  • CXCR7
Other
  • CX3C
    • CX3CR1
  • XC
    • XCR1
  • CCBP2
  • CMKLR1
TNF receptor
1-10
  • TNFR1 (TNFRSF1A)
  • TNFR2 (TNFRSF1B)
  • LTBR (TNFRSF3)
  • CD134 (TNFRSF4)
  • CD40 (TNFRSF5)
  • Fas receptor (TNFRSF6)
  • DcR3 (TNFRSF6B)
  • CD27 (TNFRSF7)
  • CD30 (TNFRSF8)
  • CD137 (TNFRSF9)
11-20
  • DR4 (TNFRSF10A)
  • DR5 (TNFRSF10B)
  • DcR1 (TNFRSF10C)
  • DcR2 (TNFRSF10D)
  • RANK (TNFRSF11A)
  • Osteoprotegerin (TNFRSF11B)
  • TweakR (TNFRSF12A)
  • TACI (TNFRSF13B)
  • BAFFR (TNFRSF13C)
  • HVEM (TNFRSF14)
  • NGFR (TNFRSF16)
  • BCMA (TNFRSF17)
  • GITR (TNFRSF18)
  • TAJ/TROY (TNFRSF19)
21-27
  • DR6 (TNFRSF21)
  • DR3 (TNFRSF25)
  • EDA2R (TNFRSF27)
JAK-STAT
Type I
γ-chain
  • Interleukin receptors
    • IL2R / IL2RA/IL2RB / IL15R
    • IL4R / IL13R / IL13RA1 / IL13RA2
    • IL7R / IL7RA
    • IL9R
    • IL21R
β-chain
  • Interleukin receptors
    • IL3R / IL3RA
    • IL5R / IL5RA
  • GM-CSF
gp130
  • Interleukin receptors
    • IL6RA
    • 11/IL11RA
    • 27/IL27RA
  • OSMR
  • LIFR
  • CNTFR
IL12RB1
  • Interleukin receptors
    • IL12R/IL12RB1/IL12RB2
    • IL23R
Other
  • other CSF receptors
    • EPO
    • G-CSF
    • Thrombopoietin
  • hormone receptor: GH
  • prolactin
Type II
  • Interleukin receptors
    • IL10R / IL10RA / IL10RB / IL22R / IL22RA1 / IL22RA2
    • IL20R / IL20RA / IL20RB
    • IL28R
  • Interferon receptors
    • -α/β / IFNAR1/IFNAR2
    • -γ/IFNGR1 / IFNGR2
Ig superfamily
  • IL1
    • IL1R1
    • IL1R2
  • IL18R / IL18R1
IL 17 family
  • IL17
    • IL17RA
    • IL17RB
    • IL17RC
    • IL17RD
    • IL17RE
Enzyme-linked receptor
  • Tyr
    • CSF1R
    • KIT
  • Ser/Thr: TGF-beta
    • TGFBR1
    • TGFBR2
    • family
  • v
  • t
  • e
Interleukin receptor modulators
IL-1
  • Agonists: Interleukin 1 (α, β)
  • Mobenakin
  • Pifonakin
  • Antagonists: AF-12198
  • Anakinra
  • IL-1RA
  • Isunakinra
  • Antibodies: Canakinumab
  • Gevokizumab
  • Lutikizumab
  • Decoy receptors: Rilonacept (IL-1 Trap)
IL-2
  • Agonists: Adargileukin alfa
  • Aldesleukin
  • Celmoleukin
  • Denileukin diftitox
  • Interleukin 2
  • Pegaldesleukin
  • Teceleukin
  • Tucotuzumab celmoleukin
  • Antibodies: Basiliximab
  • Daclizumab (dacliximab)
  • Inolimomab
IL-3
  • Agonists: Daniplestim
  • Interleukin 3
  • Leridistim
  • Milodistim
  • Muplestim
  • Promegapoietin
IL-4
  • Agonists: Binetrakin
  • Interleukin 4
  • Interleukin 13
  • Antagonists: Pitrakinra
  • Antibodies: Dupilumab
  • Pascolizumab
IL-5
  • Agonists: Interleukin 5
  • Antagonists: YM-90709
  • Antibodies: Benralizumab
  • Mepolizumab
  • Reslizumab
  • Antisense oligonucleotides: TPI ASM8
IL-6
  • Agonists: Atexakin alfa
  • Interleukin 6
  • Antibodies: ARGX-109
  • Clazakizumab
  • Elsilimomab
  • mAb 1339
  • Olokizumab
  • Sarilumab
  • Siltuximab
  • Sirukumab
  • Tocilizumab
  • Levilimab
IL-7
  • Agonists: Interleukin 7
IL-8
  • See CXCR1 (IL-8Rα) and CXCR2 (IL-8Rβ) here instead.
IL-9
  • Agonists: Interleukin 9
  • Antibodies: Enokizumab
IL-10
  • Agonists: Ilodecakin
  • Interleukin 10 (CSIF)
IL-11
  • Agonists: Interleukin 11 (AGIF)
  • Oprelvekin
IL-12
  • Agonists: Edodekin alfa
  • Interleukin 12
  • Antibodies: Briakinumab
  • Ustekinumab
IL-13
  • Agonists: Binetrakin
  • Cintredekin besudotox
  • Interleukin 4
  • Interleukin 13
  • Antibodies: Anrukinzumab
  • Lebrikizumab
  • Tralokinumab
IL-15
  • Agonists: ALT-803
  • Interleukin 15
IL-17
  • Agonists: Interleukin 17 (A, B, C, D, E (interleukin 25), F)
  • Antibodies: Brodalumab
  • Ixekizumab
  • Perakizumab
  • Remtolumab
  • Secukinumab
  • Vunakizumab
IL-18
  • Agonists: Iboctadekin
  • Interleukin 18
  • Interleukin 37
  • Tadekinig
  • Binding proteins: IL18BP
IL-20
  • Agonists: Interleukin 19
  • Interleukin 20
  • Interleukin 24
  • Antibodies: Fletikumab (against IL-20)
IL-21
  • Agonists: Denenicokin
  • Interleukin 21
  • Antibodies: NNC0114-0005
  • NNC0114-0006
IL-22
  • Agonists: Interleukin 22
  • Antibodies: Fezakinumab (against IL-22)
IL-23
  • Agonists: Interleukin 23 (SGRF)
  • Antibodies: Brazikumab
  • Briakinumab
  • Guselkumab
  • Risankizumab
  • Tildrakizumab
  • Ustekinumab
IL-27
  • Agonists: Interleukin 27 (interleukin 30)
IL-28
  • Agonists: Interferon λ4 (IFN-λ4)
  • Interleukin 28 (A (IFN-λ2), B (IFN-λ3))
  • Interleukin-29 (IFN-λ1)
IL-31
  • Agonists: Interleukin 31
IL1RL1
  • Agonists: Interleukin 33
IL1RL2
  • Agonists: Interleukin 36 (α, β, γ)
  • Interleukin 38
  • Antagonists: IL-36RA
Others
JAK
  • See here instead.
Others
  • Interleukin 14 (taxilin alpha, HMW-BCGF)
  • Interleukin 16 (signals through CD4)
  • Interleukin 24 (signals through IL-22Rα1/IL-20Rβ heterodimer)
  • Interleukin 26 (signals through IL-20Rα/IL-10Rβ heterodimer)
  • Interleukin 32
  • Interleukin 34 (signals through M-CSFR/CSF1R)
  • Interleukin 35
  • Unsorted: Efavaleukin alfa
  • Efineptakin alfa
Stub icon

This article on a gene on human chromosome 1 is a stub. You can help Wikipedia by adding missing information.

  • v
  • t
  • e
Retrieved from "https://en.wikipedia.org/w/index.php?title=IL22RA1&oldid=1221052271"
Categories:
  • Genes on human chromosome 1
  • Type II cytokine receptors
  • Human chromosome 1 gene stubs
Hidden categories:
  • Articles with short description
  • Short description matches Wikidata
  • Wikipedia articles incorporating text from the United States National Library of Medicine
  • All stub articles

  • indonesia
  • Polski
  • العربية
  • Deutsch
  • English
  • Español
  • Français
  • Italiano
  • مصرى
  • Nederlands
  • 日本語
  • Português
  • Sinugboanong Binisaya
  • Svenska
  • Українська
  • Tiếng Việt
  • Winaray
  • 中文
  • Русский
Sunting pranala
url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url
Pusat Layanan

UNIVERSITAS TEKNOKRAT INDONESIA | ASEAN's Best Private University
Jl. ZA. Pagar Alam No.9 -11, Labuhan Ratu, Kec. Kedaton, Kota Bandar Lampung, Lampung 35132
Phone: (0721) 702022
Email: pmb@teknokrat.ac.id